David Moatazedi - Jan 25, 2023 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi
Stock symbol
EOLS
Transactions as of
Jan 25, 2023
Transactions value $
$0
Form type
4
Date filed
1/27/2023, 06:24 PM
Previous filing
Aug 18, 2023
Next filing
Mar 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock Award $0 +188K +38.2% $0.00 680K Jan 25, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EOLS Stock Option (Right to Buy) Award $0 +257K $0.00 257K Jan 25, 2023 Common Stock 257K $11.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
F2 The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Remarks:

President and Chief Executive Officer